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Background: Little is known about the prevalence, predictors, and outcomes of late 
vasopressor administration which evolves after admission to the ICU. 
 
Methods: We retrospectively studied a cohort of Veterans admitted to the Veterans 
Administration ICUs for ≥ 4 days from 2014–2017. The timing of vasopressor administration 
was categorized as early (only within the initial 3 days), late (on ≥ day 4 and none on day 3) 
and continuous (within the initial 2 days through at least day 4). Regressions were performed to 
identify patient factors associated with late vasopressor administration and the timing of 
vasopressor administration with post-hospitalization discharge mortality.  
 
 Results: Among the 62,206 hospitalizations with at least 4 ICU days, late vasopressor 
administration occurred in 5.5% (N=3,429/62,206). Patients with greater co-morbidities (aOR: 
1.02 per van Walraven point, 95% CI: 1.02-1.03) and worse severity of illness on admission 
(aOR: 1.01 per percentage-point risk of death, 95% CI: 1.01-1.02) were more likely to receive 
late vasopressor therapy. Nearly 50% of patients started a new antibiotic within 24 hours of 
receiving late vasopressor therapy. One-year mortality after survival to discharge was higher for 
patients with continuous (aHR: 1.48 95% CI: 1.33-1.65) and late vasopressor administration 
(aHR: 1.26 95% CI: 1.15-1.38) as compared to only early vasopressor administration. 
 
Conclusions: Late vasopressor administration was modestly associated with co-morbidities 
and admission illness severity.  One-year mortality was higher among those who received late 
vasopressor administration as compared to only early vasopressor administration. Research to 







ICU: Intensive care unit 
VA: Veterans Administration 
VAPD: Veterans Affairs patient database 
BCMA: Barcode Medication Administration  
IQR: Interquartile range 
SOFA: Sequential organ failure assessment 
SD: Standard deviation 
OR: Odds ratio 
aOR: Adjusted odds ratio 
IRR: Incidence rate ratio 
HR: Hazard ratio 




Early recognition and appropriate treatment of cardiovascular failure improves 
mortality.1-5 Most research focused on initial presentation—particularly in the Emergency 
Department.6  However, presenting diagnoses and pathophysiology on admission to the 
intensive care unit (ICU) become less predictive of in-hospital mortality over time as a result of 
events occurring in the ICU.7-9 This suggests that caution should be used in generalizing from 
knowledge about early organ failures to the treatment and prognostic importance of later organ 
failures. 
In several cases, ICU day 4 is used to pragmatically distinguish between aspects of the 
initial resuscitation and “ICU-acquired” problems. For example, infections occurring on ICU day 
4 and beyond are distinguished from earlier occurring infections, with different recommended 
management and prognostic implications.10,11 At a single center, it was shown that 78% of 
patients with long ICU stays develop new late organ failures, most commonly cardiovascular 
failure, where “late” was also defined as occurring on day 4 and beyond.12 While the 
management of cardiovascular failure remains a core task of the modern ICU, the 
generalizability of this single center finding—the frequency and outcome of new late 
cardiovascular failure—is unknown.  
In light of this gap, we sought to evaluate the development of cardiovascular failure in 
ICU patients by evaluating the administration of vasopressor agents in a large health care 
system—the United States Veterans Administration (VA) system. We specifically hypothesized 
that late cardiovascular would be common and would be driven predominately by the 
development of sepsis.  Therefore, the objectives of the study were: 
1) To quantify the number of hospitalizations and timing when patients were receiving 
vasopressor agents; 
2) To identify patient factors associated with the development of late vasopressor 
administration.  
3) To understand the extent to which infections are associated with the development of 
late vasopressor administration 
4) To measure the one-year mortality of patients who received late vasopressor 
administration and survived to discharge and to see if it differs from those who only 




The VA health system is one of the largest integrated health care delivery systems in the 
United States with over 9 million beneficiaries and an electronic medical record which can be 
leveraged to capture granular daily data.13,14 
 
Study Population 
Data were abstracted from the Veterans Affairs Patient Database (VAPD) 2014-2017 
and represented over 100 VA hospitals.15 The VAPD contains daily standardized physiological 
information for all patients hospitalized in the VA. The information is structured at the patient-
facility-day and includes pharmacy and laboratory data, and diagnostic codes from the entire VA 
system.15,16  Analyses from the VA were approved by the IRB of the VA Ann Arbor Health 
System (IRB-2016-357). 
We abstracted data from the VAPD for all patients who were admitted to an ICU. All 
patient exclusion criteria are listed in Supplemental Appendix A. 
 
Identification of vasopressor administration 
 Vasopressor administration was defined as any intravenous receipt of norepinephrine, 
epinephrine, dopamine, phenylephrine,  
and vasopressin as recorded in the Barcode Medication Administration (BCMA) files in the 
Corporate Data Warehouse. The BCMA files include all VA inpatient medication administrations 
and includes drug name and class. The VAPD extracted all vasopressor medications.15 Drug 
infusion dose was not able to be reliably ascertained and therefore any administration on a 
given calendar day was utilized. Infusions in the operating room were not included. 
In order to quantify the timing of vasopressor administration during an ICU admission, 
we sought to distinguish four time periods. Conceptually, early vasopressor administration 
reflects the initial resuscitation and stabilization of the patient, whereas late vasopressor 
administration reflects processes that “evolved” in the ICU. Unfortunately, there is no reliable 
way to adjudicate on an individual basis such a distinction at nationwide scale with the data 
available. Therefore, following past work distinguishing community- from hospital-acquired 
pneumonia17 and early from late organ failure, we pragmatically define the first 3 days in the 
ICU as early, and day 4 and thereafter as late.12,18 Continuous vasopressor administration was 
defined as use on ICU day 1 or 2 through at least ICU day 4. Vasopressor administration which 
was not categorized as early, late, or continuous was defined as other. (Figure 1) 
A sensitivity analysis was performed to evaluate if admission to the ICU with sepsis was 
driving the administration of late vasopressor administration.18 Sepsis was defined by the Center 
of Disease and Prevention (CDC) definition of sepsis which is an EHR-based, diagnostic-code 
independent definition.19 (Supplemental Appendix B) 
 A small number of patients have prolonged ICU stays in the VA, and develop persistent 
critical illness, which may represent a distinct syndrome of cascading organ failures. We 
specifically wanted to understand the development of vasopressor administration prior to the 
onset of persistent critical illness. Using the same methods as in previously published work in 
Australia and New Zealand8 and Canada9, we found similar patterns in the onset of persistent 
illness with 10.7% of the hospitalizations with an ICU LOS greater than 11 days . 
(Supplemental Appendix C) Therefore, we examined daily vasopressor administration from 
ICU admission through ICU day 11, choosing day 11 for consistency with multiple cross-national 
sources.   
 
Identification of late infection 
 Among patients who developed late vasopressor administration, antibiotic 
administration—new or a different class of antibiotic—was reviewed within 24 hours of initiation 
of vasopressors and was used as a surrogate for suspected new infection. The VAPD included 
extraction from the BCMA files on the administration of antibiotics.15  Culture data was not able 
to be ascertained. 
 
The VA severity score 
The VA does not use the APACHE IV for severity of illness on admission. For internal 
risk-adjustment, the VA uses an illness severity measure (the VA ICU severity score), which 
predicts 30-day mortality based on several variables (age, admission diagnosis category, 29 
comorbid conditions, and 11 laboratory values). We calculated the VA severity score for each 
patient admitted to the ICU on day of admission. This severity score performs similarly to 
APACHE IV, with a C-statistic of 0.874.20  
  
Analysis 
We present patient and hospitalization characteristics as counts (percentages), means 
(SDs), or medians (interquartile ranges [IQR]) as appropriate. Elixhauser comorbidities were 
combined using the method described by van Walraven.21 We used hospitalization as the unit of 
analysis, unless otherwise specified. We used two-sided significance testing and considered a 
p-value less than 0.05 to be significant.  
 We performed logistic regression analysis to identify patient characteristics (age, gender, 
race, comorbidities) which were associated with late vasopressor administration (yes/no) while 
adjusting for severity of illness, type of ICU, hospital length of stay prior to ICU admission, 
admission diagnosis and receipt of major surgery.  To account for the number of days a patient 
could have cardiovascular organ failure, we performed a Poisson regression adjusting for the 
same co-variates to evaluate which patient characteristics were associated with the outcome, 
the number of days of late vasopressor administration. 
 Kaplan-Meier curves were utilized to evaluate 90-day in-hospital and one-year post 
discharge mortality. Among survivors, log-rank tests were performed to compare the unadjusted 
one-year mortality of those who received any vasopressors and those who never received any 
vasopressors.  90-day in-hospital and one-year post discharge mortality were evaluated using a 
Cox regression adjusting for patient characteristics, ICU type and severity of illness on 
admission. 90-day in-hospital and one-year post discharge were pragmatically chosen to 
understand if there was a difference in inpatient mortality and post-discharge mortality. The one-
year post discharge mortality was chosen given the last cohort was admitted in 2017 and death 
records were only available until 2018. The data was right sided censored at the end of 2018.  
Only the first hospitalization was used for patients with multiple admissions during the study 
period.  
We conducted all analysis with Stata software 15.1 (StataCorp, College Station, TX) and 
SAS 9.4 (SAS Institute, Cary, NC). 
 
Results: 
Of the 160,855 patients admitted to VA ICUs from 2014-2017, 62,206 had an ICU LOS 
≥ 4 days. (Figure 2) Such patients had a median age of 68 (IQR: 62, 73), were predominately 
male, and white. (Table 1) 
Overall, 18,057 hospitalizations (11.2% of 160,855) required vasopressor administration. 
Most were long stay hospitalizations (Figure 2), 13,099 (21.1% of 62,206) with ICU LOS ≥ 4 
days versus 4,958 (5.0% of 98,649) with ICU LOS < 4 days. Among all ICU patients, 
vasopressors were given only on ICU days 1-3 in 11,939 hospitalizations (4,958 with ICU LOS < 
4 days and 6,981 with ICU LOS ≥ 4 days), whereas 5,347 received them on day 4 or after. 
 Among patients admitted to the ICU for at least 4 days, late vasopressor administration 
occurred in 5.5% (N=3,429/62,206). Late vasopressor administration occurred in 9.4% 
(N=1,690/9,048) and 4.8% (N=2,574/53,158) among patients with and without sepsis on 
admission. (Figure 1 for “late” definitions, Supplemental Appendix B for additional information 
on analysis stratified by sepsis present on admission.) The median ICU day for the start of late 
vasopressor administration was ICU day 6 (IQR: 5, 7 days) with a median duration of 1 day 
(IQR: 1, 2 days).   
Of the patients with late vasopressor administration, nearly half (N=1,639/3,429) 
transitioned to a new antibiotic or a new class of antibiotic within 24 hours of the receipt of new 
vasopressors. The median duration of the new antibiotic was 3 days (IQR: 2, 5 days). 
 Among patients with at least 4 ICU days, patients with more co-morbidities (aOR: 1.02 
per van Walraven point, 95% CI:1.02-1.03: IRR 1.02, 95% CI:1.02-1.03) and higher severity of 
illness (aOR: 1.01 per percent, 95% CI: 1.01-1.02; IRR: 1.01, 95% CI: 1.01-1.02) at hospital 
admission had higher odds and higher rates of late vasopressor administration. Neither age 
(aOR: 0.98 per year, 95% CI: 0.94-1.01; IRR: 0.98, 95% CI: 0.95-1.01) nor gender (aOR:1.03 
for female vs male, 95%, CI: 0.84-1.26; IRR: 1.03, 95% CI: 0.84-1.26) were associated with 
higher odds or rates of late vasopressor administration. (Table 2)  
When stratifying patients by timing of vasopressor administration, in an unadjusted 
model, in-hospital 90-day mortality was higher among patients with late and continuous 
vasopressor administration as compared to patients with only early vasopressor administration. 
In an adjusted Cox regression model controlling for patient characteristics on admission, ICU 
type and severity of illness on admission, the adjusted hazard ratio (aHR) for in-hospital 
mortality was higher for patients who received continuous (aHR: 2.53, 95% CI: 2.26-2.84) or late 
vasopressor administration (aHR: 2.09, 95% CI: 1.88-2.33) as compared to patients who only 
received early vasopressor administration. 
Among those who survived to hospital discharge, patients who received any 
vasopressor administration had a worse one-year mortality as compared to those with no 
vasopressor requirements (unadjusted log-rank p < 0.01). (Figure 3a)  In an unadjusted model, 
when stratifying patients by timing of vasopressor administration, patients with late and 
continuous vasopressor administration, had higher one-year post-discharge mortality as 
compared to those with only early vasopressor administration. (Figure 3b).  Among those who 
survived to hospital discharge, in an adjusted Cox regression model controlling for patient 
characteristics, ICU type and severity of illness on admission, the aHR for mortality in the one 
year was higher for patients who received continuous (aHR: 1.48, 95% CI: 1.33-1.65) or late 
vasopressor administration (aHR: 1.26, 95% CI: 1.15-1.38) as compared to patients who only 




In a national cohort of Veterans admitted to the ICU, we found that 1 in 9 received any 
vasopressors and this increased to 1 in 5 among those with an ICU LOS of at least 4 days. 
Patients with a higher initial comorbidity burden and severity of illness, but not greater age, were 
somewhat more likely to be administered late vasopressors. Nearly 50% of patients with late 
vasopressor administration had a new antibiotic or a different class of antibiotic initiated within 
24 hours, suggesting that vasopressor administration was frequently associated with clinical 
concerns for recurrent or new sepsis. Late vasopressor therapy was associated with an 
increased in-hospital mortality and, among survivors, one-year post-discharge mortality among 
survivors, compared to those who used vasopressors only in the first 3 days of an ICU stay. 
 
Relationship to previous studies 
 Previous work on cardiovascular failure focused on the early presentation of 
cardiovascular failure—e.g. early goal directed therapy for sepsis and early re-vascularization 
for cardiogenic shock.1-5 Mortality rates from early cardiovascular failure have improved with the 
advancement of early detection strategies and the initiation of the appropriate treatment.22,23 
Consequently, more patients have survived their initial pathologies but have continued to remain 
in the ICU. Recent work has focused on identifying ways to limit the duration of intravenous 
vasopressors as a way of shortening ICU stays. For example, corticosteroids have reduced the 
duration of vasopressors but with potential adverse consequences.24,25 Midodrine has been 
shown in several small studies to be a beneficial adjunct in stopping intravenous vasopressors 
and is currently being evaluated in a clinical trial.26-29  These adjuncts (corticosteroids and 
midodrine) have been studied early in the ICU course.24-26 
There has been little past work systematically studying the epidemiology of late 
cardiovascular failure. Using data from the 1990s, Rosenberg et al showed that organ failures 
present later in an ICU stay (e.g. after inter-hospital transfer) had a different association with in-
hospital mortality than did those present on initial ICU presentation.7 More recently, in a single 
center cohort study, 50 patients with prolonged ICU stays were found to frequently develop new 
late organ failures on and after ICU day 4. The most common organ failure was cardiovascular 
failure.12 Our results validate and expand this concept by evaluating a large, national cohort of 
patients admitted to the ICU for at least four days. This national scope offers generalizability, 
while still maintaining a high level of clinical granularity with linked one-year mortality outcomes.   
 
Study Implications 
Cardiovascular failure which occurs later in the ICU course may have been assumed to 
have implications similar to cardiovascular failure which occurred on presentation. Our work 
questions this assumption. These data demonstrate that when a patient develops the need for 
vasopressors in their ICU stay has important mortality implications—even if the patient survives 
the hospitalization. Similar elevated post-discharge mortality has been found in sepsis, and to a 
lesser degree, acute hypoxic respiratory failure.30-32 
New late vasopressor administration, in this large national health system, is not rare—
and may benefit from targeted research with a more nuanced understanding of the physiology 
driving the administration of late vasopressor utilization in the ICU, rather than being treated by 
analogy to hypotension newly presenting to the emergency department. Our data raise an 
urgent question about the extent to which the in-ICU and post-discharge mortality, that may be 
attributable to late cardiovascular failure, are modifiable by differences in practice. 
Our findings also imply that certain patient characteristics on admission (e.g. severity of 
illness, comorbidities, race, hospital LOS prior to admission to ICU, ICU type) are associated 
with late vasopressor administration. However, the individual effect sizes are very small. 
Whether these can be meaningfully aggregated into a useful context-specific risk stratification 
tool should be a subject of future work.33,34   
Our findings demonstrate a higher mortality during and after hospitalizations with late 
vasopressor administration as compared to those hospitalizations with early vasopressor 
administration. This implies that the timing of cardiovascular failure during the ICU stay matters 
and has different survival implications.  The mechanisms driving this mortality difference needs 
to be discerned while in the ICU and in the post-hospitalization period (e.g. Post-ICU clinics). 
Additionally, our findings of associated changes in antibiotic therapy imply that sepsis—
or clinical concern for sepsis—may be partially driving the development of late vasopressor 
administration as nearly half of the patients receive a new antibiotic class within 24 hours of 
developing a requirement for vasopressors.  However, this interpretation must be tempered by 
the high propensity of U.S. hospitals to administer antibiotics, and emphasizes the need for 
more accurate point-of-care sepsis diagnostics.35  Future work would benefit from targeted 
prospective research with a more nuanced understanding of how infections are being worked up 
in the ICU, rather than being identified by analogy to the administration of antibiotics.   
 
Strengths and Limitations 
Our study has several strengths. We examined a national cohort with detailed daily 
physiologic data collected over a three-year period encompassing 62,346 hospitalizations with 
linked mortality data. These granular data allowed us to relate the timing of the need for 
vasopressors use with long-term mortality and explore the development of late vasopressor 
administration with the development of new infections. Second, we have shown that few patient 
characteristics are associated with late vasopressor therapy administration. 
 There are several limitations to our study. First, we used a cohort of Veterans who are 
disproportionately white men and may not be representative of other cohorts. However, our 
cohort also included 3.6% (N=2,236) female patients and 27.7% (N=17,203) non-white patients, 
numbers that would be substantial by themselves in many contexts. Second, we utilized 
vasopressor administration as a surrogate for cardiovascular failure. Third, it is unknown if 
changes in patient’s code status or limitations of care contributed to the differences in mortality 
and if those changes were related to the ICU admission. Fourth, we do not know if the patients 
had a documented infection when antibiotics were initiated.  
 
Conclusion 
In patients admitted to the ICU for at least 4 days, late vasopressor therapy 
administration was not uncommon and one-year mortality was higher for patients who received 
late vasopressor therapy and survived to hospital discharge compared to those who only 
received vasopressors early.  Research aimed at understanding what is driving late vasopressor 
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Table 1: Demographic and clinical features of patients who remained in the ICU ≥4 days 
  
 N=62,206 
Male, % (N) 96.4 (59,970) 
Age, median, (IQR) 68 (62, 73) 
Race, % (N)  
    White  72.3 (45,003) 
    African American 20.3 (12,597) 
    Other 7.4 (4,606) 
Type of ICU % (N)  
   Medical 55.2 (34,329) 
   Surgical 38.0 (23,651) 
   Other 6.8 (4,226) 
Elixhauser co-morbidity, median (IQR) 4 (2, 5) 
ICU LOS, median (IQR) 5 (4, 8) 
Hospital LOS, median (IQR) 9 (6,15)  
In-hospital death, % (N) 7.9 (4,931) 
Discharge location, % (N)  
    Home  89.2 (55,480) 
    Transfer to another acute care facility 3.1 (1,926) 
    Other/death 7.7 (4,800) 
ICU: Intensive Care Unit; LOS: Length of stay; IQR: Interquartile range 
 
  
Table 2: Predictors of late vasopressor administration. Association of patient-level 
characteristics comparing patients who received late vasopressors to those who did not receive 
late vasopressors. 
 
ICU: Intensive care unit; VA: Veterans Administration; LOS: Length of stay; OR: Odds ratio; CI: 





 Logistic Regression Poisson Regression 




OR 95% CI 
p-
value IRR 95% CI 
p-
value 
Age (per Decade) 1.09 <0.01 0.98 0.94-1.01 0.19 0.98 0.95-1.01 0.17 
Female (vs Male) 0.85 0.10 1.03 0.84-1.26 0.80 1.03 0.84-1.26 0.80 
 Race (vs White)       
   African   
   American 0.84 <0.01 0.87 0.79-0.95 <0.01 0.87 0.79-0.95 <0.01 
   Other 1.27 <0.01 1.18 1.04-1.33 0.01 1.18 1.04-1.33 0.01 
ICU type (vs Medical)       
   Surgical 0.91 <0.01 1.14 1.03-1.25 0.01 1.13 1.02-1.26 0.02 
   Others 0.77 <0.01 0.74 0.63-0.87 <0.01 0.74 0.63-0.87 <0.01 
Elixhauser (per van 
Walraven point) 1.03 <0.01 1.02 1.02-1.03 <0.01 1.02 1.02-1.03 <0.01 
VA risk score (per 
percent) 1.02 <0.01 1.01 1.01-1.02 <0.01 1.01 1.01-1.02 <0.01 
Operations 2.54 <0.01 2.36 2.19-2.54 <0.01 2.36 2.18-2.55 <0.01 
Hospital LOS prior to 
ICU admission (per Day) 1.03 <0.01 1.03 1.02-1.04 <0.01 1.03 1.01-1.04 <0.01 
Figure Legend 
1. The distribution of vasopressor administration by ICU day 
2. Flow diagram of hospitalizations from 2014-2017 
3. Kaplan-Meier Survival Curves one year after hospitalization discharge among those with 
an ICU LOS ≥ 4 days  
 
 
